G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value

Namhoon Cho, Shin Young Lim, YoungTae Kim, Dongki Kim, Young Sun Kim, Jae Wook Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction. We aimed to verify not only whether homozygous Arg at codon 72 of the p53 apoptotic domain is a possible risk factor for cervical human papillomavirus (HPV)-related cancer, but whether degraded p53 may have an effect on a G2 checkpoint of the cell cycle. The implication of the codon 72 polymorphism of p53 in cervical tumor remains controversial. Furthermore, G2 checkpoint alteration and its relationship with p53, the codon 72 allotype, according to HPV infection in cervical tumors, has not been studied. Materials and methods. The purified genomic DNA from 252 archival cervical tissues [102 cervical intraepithelial neoplasias (CINs) and 46 squamous cell carcinomas of the uterine cervix (SCCs), and 104 normal] were amplified by nested polymerase chain reaction (PCR) for HPV-16/HPV-18. In addition, all of them were amplified by PCR for exon 4 of p53, where the codon 72 resides. The amplified PCR products were then sequenced using the forward primer. A polymorphism analysis was done by SnaPshot ddNTP primer extension and following direct sequencing. The reaction mixture was treated with 0.25 unit of shrimp alkaline phosphatase (Amersham) at 37°C for 1 h, subsequently performed in an ABI Prism 310 Genetic Analyzer (Perkin-Elmer). The archival slides were incubated overnight at 4°C using mouse anti-human recombinant cyclin B1 polyclonal antibody or mouse anti-Xenopus p34cdc2 monoclonal antibody for immunohistochemistry (Santa Cruz Biotech, Santa Cruz, CA). Results. The frequency of Arg allelic homozygosity was high in both cases (89.1%) and the control (80.8%) group (P = 0.4703). All groups except CIN were in Hardy-Weinberg equilibrium. There was no significant difference in the frequency of p53 polymorphism between the HPV-positive (Arg, 88.0%) and the negative (Arg, 88.8%) groups, or between CIN (Arg, 88.2%) and SCC (Arg, 89.1%). Both immunoreactivities to cyclin B and p34cdc2 were strongly correlated with the HPV infection (P = 0.0001) and the histological types (P = 0.0001) between CIN and SCC, being strongly correlated with each other (α:0.62954, P = 0.0001). Conclusion. The particular type of the p53 polymorphism does not bear relation to the progression of cervical cancer, HPV infection, or to the p53 codon 72 polymorphism. However, the G2 checkpoint appears to be altered in the case of a HPV-positive SCC.

Original languageEnglish
Pages (from-to)15-22
Number of pages8
JournalGynecologic Oncology
Volume90
Issue number1
DOIs
Publication statusPublished - 2003 Jan 1

Fingerprint

Human papillomavirus 16
Uterine Cervical Neoplasms
Cervical Intraepithelial Neoplasia
Codon
Papillomavirus Infections
Polymerase Chain Reaction
Dideoxynucleotides
G2 Phase Cell Cycle Checkpoints
Cyclin B
Cyclin B1
Human papillomavirus 18
Neoplasms
Xenopus
Cervix Uteri
Alkaline Phosphatase
Squamous Cell Carcinoma
Exons
Immunohistochemistry
Monoclonal Antibodies
Control Groups

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Cho, Namhoon ; Lim, Shin Young ; Kim, YoungTae ; Kim, Dongki ; Kim, Young Sun ; Kim, Jae Wook. / G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value. In: Gynecologic Oncology. 2003 ; Vol. 90, No. 1. pp. 15-22.
@article{2a9e0ad798db48e88fc9f8ad3214d1be,
title = "G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value",
abstract = "Introduction. We aimed to verify not only whether homozygous Arg at codon 72 of the p53 apoptotic domain is a possible risk factor for cervical human papillomavirus (HPV)-related cancer, but whether degraded p53 may have an effect on a G2 checkpoint of the cell cycle. The implication of the codon 72 polymorphism of p53 in cervical tumor remains controversial. Furthermore, G2 checkpoint alteration and its relationship with p53, the codon 72 allotype, according to HPV infection in cervical tumors, has not been studied. Materials and methods. The purified genomic DNA from 252 archival cervical tissues [102 cervical intraepithelial neoplasias (CINs) and 46 squamous cell carcinomas of the uterine cervix (SCCs), and 104 normal] were amplified by nested polymerase chain reaction (PCR) for HPV-16/HPV-18. In addition, all of them were amplified by PCR for exon 4 of p53, where the codon 72 resides. The amplified PCR products were then sequenced using the forward primer. A polymorphism analysis was done by SnaPshot ddNTP primer extension and following direct sequencing. The reaction mixture was treated with 0.25 unit of shrimp alkaline phosphatase (Amersham) at 37°C for 1 h, subsequently performed in an ABI Prism 310 Genetic Analyzer (Perkin-Elmer). The archival slides were incubated overnight at 4°C using mouse anti-human recombinant cyclin B1 polyclonal antibody or mouse anti-Xenopus p34cdc2 monoclonal antibody for immunohistochemistry (Santa Cruz Biotech, Santa Cruz, CA). Results. The frequency of Arg allelic homozygosity was high in both cases (89.1{\%}) and the control (80.8{\%}) group (P = 0.4703). All groups except CIN were in Hardy-Weinberg equilibrium. There was no significant difference in the frequency of p53 polymorphism between the HPV-positive (Arg, 88.0{\%}) and the negative (Arg, 88.8{\%}) groups, or between CIN (Arg, 88.2{\%}) and SCC (Arg, 89.1{\%}). Both immunoreactivities to cyclin B and p34cdc2 were strongly correlated with the HPV infection (P = 0.0001) and the histological types (P = 0.0001) between CIN and SCC, being strongly correlated with each other (α:0.62954, P = 0.0001). Conclusion. The particular type of the p53 polymorphism does not bear relation to the progression of cervical cancer, HPV infection, or to the p53 codon 72 polymorphism. However, the G2 checkpoint appears to be altered in the case of a HPV-positive SCC.",
author = "Namhoon Cho and Lim, {Shin Young} and YoungTae Kim and Dongki Kim and Kim, {Young Sun} and Kim, {Jae Wook}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S0090-8258(03)00198-7",
language = "English",
volume = "90",
pages = "15--22",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value. / Cho, Namhoon; Lim, Shin Young; Kim, YoungTae; Kim, Dongki; Kim, Young Sun; Kim, Jae Wook.

In: Gynecologic Oncology, Vol. 90, No. 1, 01.01.2003, p. 15-22.

Research output: Contribution to journalArticle

TY - JOUR

T1 - G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value

AU - Cho, Namhoon

AU - Lim, Shin Young

AU - Kim, YoungTae

AU - Kim, Dongki

AU - Kim, Young Sun

AU - Kim, Jae Wook

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Introduction. We aimed to verify not only whether homozygous Arg at codon 72 of the p53 apoptotic domain is a possible risk factor for cervical human papillomavirus (HPV)-related cancer, but whether degraded p53 may have an effect on a G2 checkpoint of the cell cycle. The implication of the codon 72 polymorphism of p53 in cervical tumor remains controversial. Furthermore, G2 checkpoint alteration and its relationship with p53, the codon 72 allotype, according to HPV infection in cervical tumors, has not been studied. Materials and methods. The purified genomic DNA from 252 archival cervical tissues [102 cervical intraepithelial neoplasias (CINs) and 46 squamous cell carcinomas of the uterine cervix (SCCs), and 104 normal] were amplified by nested polymerase chain reaction (PCR) for HPV-16/HPV-18. In addition, all of them were amplified by PCR for exon 4 of p53, where the codon 72 resides. The amplified PCR products were then sequenced using the forward primer. A polymorphism analysis was done by SnaPshot ddNTP primer extension and following direct sequencing. The reaction mixture was treated with 0.25 unit of shrimp alkaline phosphatase (Amersham) at 37°C for 1 h, subsequently performed in an ABI Prism 310 Genetic Analyzer (Perkin-Elmer). The archival slides were incubated overnight at 4°C using mouse anti-human recombinant cyclin B1 polyclonal antibody or mouse anti-Xenopus p34cdc2 monoclonal antibody for immunohistochemistry (Santa Cruz Biotech, Santa Cruz, CA). Results. The frequency of Arg allelic homozygosity was high in both cases (89.1%) and the control (80.8%) group (P = 0.4703). All groups except CIN were in Hardy-Weinberg equilibrium. There was no significant difference in the frequency of p53 polymorphism between the HPV-positive (Arg, 88.0%) and the negative (Arg, 88.8%) groups, or between CIN (Arg, 88.2%) and SCC (Arg, 89.1%). Both immunoreactivities to cyclin B and p34cdc2 were strongly correlated with the HPV infection (P = 0.0001) and the histological types (P = 0.0001) between CIN and SCC, being strongly correlated with each other (α:0.62954, P = 0.0001). Conclusion. The particular type of the p53 polymorphism does not bear relation to the progression of cervical cancer, HPV infection, or to the p53 codon 72 polymorphism. However, the G2 checkpoint appears to be altered in the case of a HPV-positive SCC.

AB - Introduction. We aimed to verify not only whether homozygous Arg at codon 72 of the p53 apoptotic domain is a possible risk factor for cervical human papillomavirus (HPV)-related cancer, but whether degraded p53 may have an effect on a G2 checkpoint of the cell cycle. The implication of the codon 72 polymorphism of p53 in cervical tumor remains controversial. Furthermore, G2 checkpoint alteration and its relationship with p53, the codon 72 allotype, according to HPV infection in cervical tumors, has not been studied. Materials and methods. The purified genomic DNA from 252 archival cervical tissues [102 cervical intraepithelial neoplasias (CINs) and 46 squamous cell carcinomas of the uterine cervix (SCCs), and 104 normal] were amplified by nested polymerase chain reaction (PCR) for HPV-16/HPV-18. In addition, all of them were amplified by PCR for exon 4 of p53, where the codon 72 resides. The amplified PCR products were then sequenced using the forward primer. A polymorphism analysis was done by SnaPshot ddNTP primer extension and following direct sequencing. The reaction mixture was treated with 0.25 unit of shrimp alkaline phosphatase (Amersham) at 37°C for 1 h, subsequently performed in an ABI Prism 310 Genetic Analyzer (Perkin-Elmer). The archival slides were incubated overnight at 4°C using mouse anti-human recombinant cyclin B1 polyclonal antibody or mouse anti-Xenopus p34cdc2 monoclonal antibody for immunohistochemistry (Santa Cruz Biotech, Santa Cruz, CA). Results. The frequency of Arg allelic homozygosity was high in both cases (89.1%) and the control (80.8%) group (P = 0.4703). All groups except CIN were in Hardy-Weinberg equilibrium. There was no significant difference in the frequency of p53 polymorphism between the HPV-positive (Arg, 88.0%) and the negative (Arg, 88.8%) groups, or between CIN (Arg, 88.2%) and SCC (Arg, 89.1%). Both immunoreactivities to cyclin B and p34cdc2 were strongly correlated with the HPV infection (P = 0.0001) and the histological types (P = 0.0001) between CIN and SCC, being strongly correlated with each other (α:0.62954, P = 0.0001). Conclusion. The particular type of the p53 polymorphism does not bear relation to the progression of cervical cancer, HPV infection, or to the p53 codon 72 polymorphism. However, the G2 checkpoint appears to be altered in the case of a HPV-positive SCC.

UR - http://www.scopus.com/inward/record.url?scp=0038162291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038162291&partnerID=8YFLogxK

U2 - 10.1016/S0090-8258(03)00198-7

DO - 10.1016/S0090-8258(03)00198-7

M3 - Article

VL - 90

SP - 15

EP - 22

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -